Amended Statement of Beneficial Ownership (3/a)

Date : 08/29/2019 @ 3:34PM
Source : Edgar (US Regulatory)
Stock : Aridis Pharmaceuticals Inc (ARDS)
Quote : 6.74  -0.02 (-0.30%) @ 9:06PM
Aridis Pharmaceuticals share price Chart

Amended Statement of Beneficial Ownership (3/a)

FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

KURLAND FRED

2. Date of Event Requiring Statement (MM/DD/YYYY)
8/13/2018 

3. Issuer Name and Ticker or Trading Symbol

Aridis Pharmaceuticals, Inc. [ARDS]

(Last)        (First)        (Middle)

C/O ARIDIS PHARMACEUTICALS, INC., 5491 OPTICAL CT.

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Financial Officer /

(Street)

SAN JOSE, CA 95138      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)

8/13/2018 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options 6/1/2017 (1)9/5/2024 Common Stock 6493 $2.89 D  
Stock Options 12/6/2017 3/6/2025 Common Stock 5455 (2)$2.89 D  

Explanation of Responses:
(1) The original form 3 reported that the stock options were exercisable beginning on 09/01/2017.
(2) The original form 3 reported the amount as 5,454 (a one share difference).

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
KURLAND FRED
C/O ARIDIS PHARMACEUTICALS, INC.
5491 OPTICAL CT.
SAN JOSE, CA 95138


Chief Financial Officer

Signatures
/s/ Fred Kurland8/29/2019
**Signature of Reporting PersonDate

Aridis Pharmaceuticals (NASDAQ:ARDS)
Historical Stock Chart

1 Year : From Mar 2019 to Feb 2020

Click Here for more Aridis Pharmaceuticals Charts.

Aridis Pharmaceuticals (NASDAQ:ARDS)
Intraday Stock Chart

Today : Saturday 29 February 2020

Click Here for more Aridis Pharmaceuticals Charts.

Latest ARDS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200229 05:16:31